Moreover, we highlight the dual-specificity Chk1/Chk2 inhibitor, prexasertib, which has completed phase 2 trials for cancer, that has potent neuroprotective effects at low doses and is a viable candidate to repurpose for treating CNS injuries, SCI. Here, CHEK1 is linked to cancer.